APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-inflammatory and Antipyretic Granules

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Anti-inflammatory and Antipyretic Granules Market Outlook and Growth Opportunities 2026

27 December 2025206 pages

Choose your research edition.

Industry ResearchAnti-inflammatory and Antipyretic Granules Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-inflammatory and Antipyretic Granules Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Anti-inflammatory and Antipyretic Granules Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-inflammatory and Antipyretic Granules Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-inflammatory and Antipyretic Granules Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Anti-inflammatory and Antipyretic Granules market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Anti-inflammatory and Antipyretic Granules is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Anti-inflammatory and Antipyretic Granules is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Anti-inflammatory and Antipyretic Granules is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Anti-inflammatory and Antipyretic Granules market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Anti-inflammatory and Antipyretic Granules market include Dong'e Ejiao Co., Ltd., Guangdong Baihe Pharmaceutical Co., Ltd., Guangxi Tiantianle Pharmaceutical Co., Ltd., Hebei Tiancheng Pharmaceutical Co., Ltd., Hubei Dongxin Pharmaceutical Co., Ltd., Hubei Nordeson Pharmaceutical Co., Ltd., Jilin Xianfeng Technology Pharmaceutical Co., Ltd., Jiangxi Jimin Kexin Pharmaceutical Co., Ltd. and Liaoning Xingao Pharmaceutical Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Anti-inflammatory and Antipyretic Granules market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Anti-inflammatory and Antipyretic Granules and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Anti-inflammatory and Antipyretic Granules sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Anti-inflammatory and Antipyretic Granules market size, projected growth trends, production technologies, key applications, and end-use industries.

Anti-inflammatory and Antipyretic Granules Segment by Company

Dong'e Ejiao Co., Ltd.

Guangdong Baihe Pharmaceutical Co., Ltd.

Guangxi Tiantianle Pharmaceutical Co., Ltd.

Hebei Tiancheng Pharmaceutical Co., Ltd.

Hubei Dongxin Pharmaceutical Co., Ltd.

Hubei Nordeson Pharmaceutical Co., Ltd.

Jilin Xianfeng Technology Pharmaceutical Co., Ltd.

Jiangxi Jimin Kexin Pharmaceutical Co., Ltd.

Liaoning Xingao Pharmaceutical Co., Ltd.

Nanning Kangnuo Biochemical Pharmaceutical Co., Ltd.

Shaanxi Buchang Pharmaceutical Co., Ltd.

Shaanxi Han Tang Pharmaceutical Co., Ltd.

Shenyang Junyuan Pharmaceutical Co., Ltd.

Sichuan Kelun Pharmaceutical Co., Ltd.

Sichuan Luye Pharmaceutical Co., Ltd.

Yunnan Baiyao Group Co., Ltd.

Yunnan Longfa Pharmaceutical Co., Ltd.

Anti-inflammatory and Antipyretic Granules Segment by Type

Pack of 10

Pack of 16

Anti-inflammatory and Antipyretic Granules Segment by Application

Online Sales

Offline Sales

Anti-inflammatory and Antipyretic Granules Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Anti-inflammatory and Antipyretic Granules status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Anti-inflammatory and Antipyretic Granules market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Anti-inflammatory and Antipyretic Granules significant trends, drivers, influence factors in global and regions.

6. To analyze Anti-inflammatory and Antipyretic Granules competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-inflammatory and Antipyretic Granules market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-inflammatory and Antipyretic Granules and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-inflammatory and Antipyretic Granules.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Anti-inflammatory and Antipyretic Granules market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Anti-inflammatory and Antipyretic Granules industry.

Chapter 3: Detailed analysis of Anti-inflammatory and Antipyretic Granules manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Anti-inflammatory and Antipyretic Granules in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Anti-inflammatory and Antipyretic Granules in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Anti-inflammatory and Antipyretic Granules Industry Trends Table 2. Anti-inflammatory and Antipyretic Granules Industry Drivers Table 3. Anti-inflammatory and Antipyretic Granules Industry Opportunities and Challenges Table 4. Anti-inflammatory and Antipyretic Granules Industry Restraints Table 5. Global Anti-inflammatory and Antipyretic Granules Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Anti-inflammatory and Antipyretic Granules Revenue Share by Company (2021-2026) Table 7. Global Anti-inflammatory and Antipyretic Granules Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Anti-inflammatory and Antipyretic Granules Sales Volume Share by Company (2021-2026) Table 9. Global Anti-inflammatory and Antipyretic Granules Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Anti-inflammatory and Antipyretic Granules Company Ranking, (2024-2026) & (USD Million) Table 11. Global Anti-inflammatory and Antipyretic Granules Key Company Manufacturing Base & Headquarters Table 12. Global Anti-inflammatory and Antipyretic Granules Company, Product Type & Application Table 13. Global Anti-inflammatory and Antipyretic Granules Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Anti-inflammatory and Antipyretic Granules by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Pack of 10 Table 18. Significant Companies of Pack of 16 Table 19. Global Anti-inflammatory and Antipyretic Granules Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Anti-inflammatory and Antipyretic Granules Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Anti-inflammatory and Antipyretic Granules Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Anti-inflammatory and Antipyretic Granules Sales Volume Share by Type (2021-2026) Table 23. Global Anti-inflammatory and Antipyretic Granules Sales Volume Share by Type (2027-2032) Table 24. Global Anti-inflammatory and Antipyretic Granules Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Anti-inflammatory and Antipyretic Granules Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Anti-inflammatory and Antipyretic Granules Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Anti-inflammatory and Antipyretic Granules Sales Value Share by Type (2021-2026) Table 28. Global Anti-inflammatory and Antipyretic Granules Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Online Sales Table 30. Significant Companies of Offline Sales Table 31. Global Anti-inflammatory and Antipyretic Granules Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Anti-inflammatory and Antipyretic Granules Sales Volume by Application (2021-2026) & (K Units) Table 33. Global Anti-inflammatory and Antipyretic Granules Sales Volume by Application (2027-2032) & (K Units) Table 34. Global Anti-inflammatory and Antipyretic Granules Sales Volume Share by Application (2021-2026) Table 35. Global Anti-inflammatory and Antipyretic Granules Sales Volume Share by Application (2027-2032) Table 36. Global Anti-inflammatory and Antipyretic Granules Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Anti-inflammatory and Antipyretic Granules Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Anti-inflammatory and Antipyretic Granules Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Anti-inflammatory and Antipyretic Granules Sales Value Share by Application (2021-2026) Table 40. Global Anti-inflammatory and Antipyretic Granules Sales Value Share by Application (2027-2032) Table 41. Global Anti-inflammatory and Antipyretic Granules Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Anti-inflammatory and Antipyretic Granules Sales by Region (2021-2026) & (K Units) Table 43. Global Anti-inflammatory and Antipyretic Granules Sales Market Share by Region (2021-2026) Table 44. Global Anti-inflammatory and Antipyretic Granules Sales by Region (2027-2032) & (K Units) Table 45. Global Anti-inflammatory and Antipyretic Granules Sales Market Share by Region (2027-2032) Table 46. Global Anti-inflammatory and Antipyretic Granules Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Anti-inflammatory and Antipyretic Granules Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Anti-inflammatory and Antipyretic Granules Sales Value Share by Region (2021-2026) Table 49. Global Anti-inflammatory and Antipyretic Granules Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Anti-inflammatory and Antipyretic Granules Sales Value Share by Region (2027-2032) Table 51. Global Anti-inflammatory and Antipyretic Granules Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global Anti-inflammatory and Antipyretic Granules Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global Anti-inflammatory and Antipyretic Granules Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Global Anti-inflammatory and Antipyretic Granules Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Anti-inflammatory and Antipyretic Granules Sales by Country (2021-2026) & (K Units) Table 56. Global Anti-inflammatory and Antipyretic Granules Sales Market Share by Country (2021-2026) Table 57. Global Anti-inflammatory and Antipyretic Granules Sales by Country (2027-2032) & (K Units) Table 58. Global Anti-inflammatory and Antipyretic Granules Sales Market Share by Country (2027-2032) Table 59. Global Anti-inflammatory and Antipyretic Granules Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Anti-inflammatory and Antipyretic Granules Sales Value Market Share by Country (2021-2026) Table 61. Global Anti-inflammatory and Antipyretic Granules Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Anti-inflammatory and Antipyretic Granules Sales Value Market Share by Country (2027-2032) Table 63. Dong'e Ejiao Co., Ltd. Company Information Table 64. Dong'e Ejiao Co., Ltd. Business Overview Table 65. Dong'e Ejiao Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Dong'e Ejiao Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Portfolio Table 67. Dong'e Ejiao Co., Ltd. Recent Development Table 68. Guangdong Baihe Pharmaceutical Co., Ltd. Company Information Table 69. Guangdong Baihe Pharmaceutical Co., Ltd. Business Overview Table 70. Guangdong Baihe Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Guangdong Baihe Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Portfolio Table 72. Guangdong Baihe Pharmaceutical Co., Ltd. Recent Development Table 73. Guangxi Tiantianle Pharmaceutical Co., Ltd. Company Information Table 74. Guangxi Tiantianle Pharmaceutical Co., Ltd. Business Overview Table 75. Guangxi Tiantianle Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Guangxi Tiantianle Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Portfolio Table 77. Guangxi Tiantianle Pharmaceutical Co., Ltd. Recent Development Table 78. Hebei Tiancheng Pharmaceutical Co., Ltd. Company Information Table 79. Hebei Tiancheng Pharmaceutical Co., Ltd. Business Overview Table 80. Hebei Tiancheng Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Hebei Tiancheng Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Portfolio Table 82. Hebei Tiancheng Pharmaceutical Co., Ltd. Recent Development Table 83. Hubei Dongxin Pharmaceutical Co., Ltd. Company Information Table 84. Hubei Dongxin Pharmaceutical Co., Ltd. Business Overview Table 85. Hubei Dongxin Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Hubei Dongxin Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Portfolio Table 87. Hubei Dongxin Pharmaceutical Co., Ltd. Recent Development Table 88. Hubei Nordeson Pharmaceutical Co., Ltd. Company Information Table 89. Hubei Nordeson Pharmaceutical Co., Ltd. Business Overview Table 90. Hubei Nordeson Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Hubei Nordeson Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Portfolio Table 92. Hubei Nordeson Pharmaceutical Co., Ltd. Recent Development Table 93. Jilin Xianfeng Technology Pharmaceutical Co., Ltd. Company Information Table 94. Jilin Xianfeng Technology Pharmaceutical Co., Ltd. Business Overview Table 95. Jilin Xianfeng Technology Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Jilin Xianfeng Technology Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Portfolio Table 97. Jilin Xianfeng Technology Pharmaceutical Co., Ltd. Recent Development Table 98. Jiangxi Jimin Kexin Pharmaceutical Co., Ltd. Company Information Table 99. Jiangxi Jimin Kexin Pharmaceutical Co., Ltd. Business Overview Table 100. Jiangxi Jimin Kexin Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Jiangxi Jimin Kexin Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Portfolio Table 102. Jiangxi Jimin Kexin Pharmaceutical Co., Ltd. Recent Development Table 103. Liaoning Xingao Pharmaceutical Co., Ltd. Company Information Table 104. Liaoning Xingao Pharmaceutical Co., Ltd. Business Overview Table 105. Liaoning Xingao Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Liaoning Xingao Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Portfolio Table 107. Liaoning Xingao Pharmaceutical Co., Ltd. Recent Development Table 108. Nanning Kangnuo Biochemical Pharmaceutical Co., Ltd. Company Information Table 109. Nanning Kangnuo Biochemical Pharmaceutical Co., Ltd. Business Overview Table 110. Nanning Kangnuo Biochemical Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Nanning Kangnuo Biochemical Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Portfolio Table 112. Nanning Kangnuo Biochemical Pharmaceutical Co., Ltd. Recent Development Table 113. Shaanxi Buchang Pharmaceutical Co., Ltd. Company Information Table 114. Shaanxi Buchang Pharmaceutical Co., Ltd. Business Overview Table 115. Shaanxi Buchang Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Shaanxi Buchang Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Portfolio Table 117. Shaanxi Buchang Pharmaceutical Co., Ltd. Recent Development Table 118. Shaanxi Han Tang Pharmaceutical Co., Ltd. Company Information Table 119. Shaanxi Han Tang Pharmaceutical Co., Ltd. Business Overview Table 120. Shaanxi Han Tang Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Shaanxi Han Tang Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Portfolio Table 122. Shaanxi Han Tang Pharmaceutical Co., Ltd. Recent Development Table 123. Shenyang Junyuan Pharmaceutical Co., Ltd. Company Information Table 124. Shenyang Junyuan Pharmaceutical Co., Ltd. Business Overview Table 125. Shenyang Junyuan Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Shenyang Junyuan Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Portfolio Table 127. Shenyang Junyuan Pharmaceutical Co., Ltd. Recent Development Table 128. Sichuan Kelun Pharmaceutical Co., Ltd. Company Information Table 129. Sichuan Kelun Pharmaceutical Co., Ltd. Business Overview Table 130. Sichuan Kelun Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Sichuan Kelun Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Portfolio Table 132. Sichuan Kelun Pharmaceutical Co., Ltd. Recent Development Table 133. Sichuan Luye Pharmaceutical Co., Ltd. Company Information Table 134. Sichuan Luye Pharmaceutical Co., Ltd. Business Overview Table 135. Sichuan Luye Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Sichuan Luye Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Portfolio Table 137. Sichuan Luye Pharmaceutical Co., Ltd. Recent Development Table 138. Yunnan Baiyao Group Co., Ltd. Company Information Table 139. Yunnan Baiyao Group Co., Ltd. Business Overview Table 140. Yunnan Baiyao Group Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. Yunnan Baiyao Group Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Portfolio Table 142. Yunnan Baiyao Group Co., Ltd. Recent Development Table 143. Yunnan Longfa Pharmaceutical Co., Ltd. Company Information Table 144. Yunnan Longfa Pharmaceutical Co., Ltd. Business Overview Table 145. Yunnan Longfa Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 146. Yunnan Longfa Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Portfolio Table 147. Yunnan Longfa Pharmaceutical Co., Ltd. Recent Development Table 148. Key Raw Materials Table 149. Raw Materials Key Suppliers Table 150. Anti-inflammatory and Antipyretic Granules Distributors List Table 151. Anti-inflammatory and Antipyretic Granules Customers List Table 152. Research Programs/Design for This Report Table 153. Authors List of This Report Table 154. Secondary Sources Table 155. Primary Sources List of Figures Figure 1. Anti-inflammatory and Antipyretic Granules Product Image Figure 2. Global Anti-inflammatory and Antipyretic Granules Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-inflammatory and Antipyretic Granules Sales Value (2021-2032) & (US$ Million) Figure 4. Global Anti-inflammatory and Antipyretic Granules Sales (2021-2032) & (K Units) Figure 5. Global Anti-inflammatory and Antipyretic Granules Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Anti-inflammatory and Antipyretic Granules Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Pack of 10 Image Figure 10. Pack of 16 Image Figure 11. Global Anti-inflammatory and Antipyretic Granules Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Anti-inflammatory and Antipyretic Granules Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Anti-inflammatory and Antipyretic Granules Sales Volume Share by Type (2021-2032) Figure 14. Global Anti-inflammatory and Antipyretic Granules Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Anti-inflammatory and Antipyretic Granules Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Anti-inflammatory and Antipyretic Granules Sales Value Share by Type (2021-2032) Figure 17. Online Sales Image Figure 18. Offline Sales Image Figure 19. Global Anti-inflammatory and Antipyretic Granules Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Anti-inflammatory and Antipyretic Granules Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Anti-inflammatory and Antipyretic Granules Sales Volume Share by Application (2021-2032) Figure 22. Global Anti-inflammatory and Antipyretic Granules Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Anti-inflammatory and Antipyretic Granules Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Anti-inflammatory and Antipyretic Granules Sales Value Share by Application (2021-2032) Figure 25. Global Anti-inflammatory and Antipyretic Granules Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 26. Global Anti-inflammatory and Antipyretic Granules Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Anti-inflammatory and Antipyretic Granules Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Anti-inflammatory and Antipyretic Granules Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Anti-inflammatory and Antipyretic Granules Sales Value (2021-2032) & (US$ Million) Figure 30. North America Anti-inflammatory and Antipyretic Granules Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Anti-inflammatory and Antipyretic Granules Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Anti-inflammatory and Antipyretic Granules Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Anti-inflammatory and Antipyretic Granules Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Anti-inflammatory and Antipyretic Granules Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Anti-inflammatory and Antipyretic Granules Sales Value (2021-2032) & (US$ Million) Figure 36. South America Anti-inflammatory and Antipyretic Granules Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Anti-inflammatory and Antipyretic Granules Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Anti-inflammatory and Antipyretic Granules Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Anti-inflammatory and Antipyretic Granules Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Anti-inflammatory and Antipyretic Granules Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Pack of 10
  • Pack of 16
Applications
  • Online Sales
  • Offline Sales
Companies covered
  • Dong'e Ejiao Co., Ltd.
  • Guangdong Baihe Pharmaceutical Co., Ltd.
  • Guangxi Tiantianle Pharmaceutical Co., Ltd.
  • Hebei Tiancheng Pharmaceutical Co., Ltd.
  • Hubei Dongxin Pharmaceutical Co., Ltd.
  • Hubei Nordeson Pharmaceutical Co., Ltd.
  • Jilin Xianfeng Technology Pharmaceutical Co., Ltd.
  • Jiangxi Jimin Kexin Pharmaceutical Co., Ltd.
  • Liaoning Xingao Pharmaceutical Co., Ltd.
  • Nanning Kangnuo Biochemical Pharmaceutical Co., Ltd.
  • Shaanxi Buchang Pharmaceutical Co., Ltd.
  • Shaanxi Han Tang Pharmaceutical Co., Ltd.
  • Shenyang Junyuan Pharmaceutical Co., Ltd.
  • Sichuan Kelun Pharmaceutical Co., Ltd.
  • Sichuan Luye Pharmaceutical Co., Ltd.
  • Yunnan Baiyao Group Co., Ltd.
  • Yunnan Longfa Pharmaceutical Co., Ltd.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Anti-inflammatory and Antipyretic Granules Sales Value (2021-2032)
  4. 1.2.2 Global Anti-inflammatory and Antipyretic Granules Sales Volume (2021-2032)
  5. 1.2.3 Global Anti-inflammatory and Antipyretic Granules Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Anti-inflammatory and Antipyretic Granules Market Dynamics
  1. 2.1 Anti-inflammatory and Antipyretic Granules Industry Trends
  2. 2.2 Anti-inflammatory and Antipyretic Granules Industry Drivers
  3. 2.3 Anti-inflammatory and Antipyretic Granules Industry Opportunities and Challenges
  4. 2.4 Anti-inflammatory and Antipyretic Granules Industry Restraints
3 Anti-inflammatory and Antipyretic Granules Market by Company
  1. 3.1 Global Anti-inflammatory and Antipyretic Granules Company Revenue Ranking in 2025
  2. 3.2 Global Anti-inflammatory and Antipyretic Granules Revenue by Company (2021-2026)
  3. 3.3 Global Anti-inflammatory and Antipyretic Granules Sales Volume by Company (2021-2026)
  4. 3.4 Global Anti-inflammatory and Antipyretic Granules Average Price by Company (2021-2026)
  5. 3.5 Global Anti-inflammatory and Antipyretic Granules Company Ranking (2024-2026)
  6. 3.6 Global Anti-inflammatory and Antipyretic Granules Company Manufacturing Base and Headquarters
  7. 3.7 Global Anti-inflammatory and Antipyretic Granules Company Product Type and Application
  8. 3.8 Global Anti-inflammatory and Antipyretic Granules Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Anti-inflammatory and Antipyretic Granules Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Anti-inflammatory and Antipyretic Granules Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Anti-inflammatory and Antipyretic Granules Market by Type
  1. 4.1 Anti-inflammatory and Antipyretic Granules Type Introduction
  2. 4.1.1 Pack of 10
  3. 4.1.2 Pack of 16
  4. 4.2 Global Anti-inflammatory and Antipyretic Granules Sales Volume by Type
  5. 4.2.1 Global Anti-inflammatory and Antipyretic Granules Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Anti-inflammatory and Antipyretic Granules Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Anti-inflammatory and Antipyretic Granules Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Anti-inflammatory and Antipyretic Granules Sales Value by Type
  9. 4.3.1 Global Anti-inflammatory and Antipyretic Granules Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Anti-inflammatory and Antipyretic Granules Sales Value by Type (2021-2032)
  11. 4.3.3 Global Anti-inflammatory and Antipyretic Granules Sales Value Share by Type (2021-2032)
5 Anti-inflammatory and Antipyretic Granules Market by Application
  1. 5.1 Anti-inflammatory and Antipyretic Granules Application Introduction
  2. 5.1.1 Online Sales
  3. 5.1.2 Offline Sales
  4. 5.2 Global Anti-inflammatory and Antipyretic Granules Sales Volume by Application
  5. 5.2.1 Global Anti-inflammatory and Antipyretic Granules Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Anti-inflammatory and Antipyretic Granules Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Anti-inflammatory and Antipyretic Granules Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Anti-inflammatory and Antipyretic Granules Sales Value by Application
  9. 5.3.1 Global Anti-inflammatory and Antipyretic Granules Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Anti-inflammatory and Antipyretic Granules Sales Value by Application (2021-2032)
  11. 5.3.3 Global Anti-inflammatory and Antipyretic Granules Sales Value Share by Application (2021-2032)
6 Anti-inflammatory and Antipyretic Granules Regional Sales and Value Analysis
  1. 6.1 Global Anti-inflammatory and Antipyretic Granules Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Anti-inflammatory and Antipyretic Granules Sales by Region (2021-2032)
  3. 6.2.1 Global Anti-inflammatory and Antipyretic Granules Sales by Region: 2021-2026
  4. 6.2.2 Global Anti-inflammatory and Antipyretic Granules Sales by Region (2027-2032)
  5. 6.3 Global Anti-inflammatory and Antipyretic Granules Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Anti-inflammatory and Antipyretic Granules Sales Value by Region (2021-2032)
  7. 6.4.1 Global Anti-inflammatory and Antipyretic Granules Sales Value by Region: 2021-2026
  8. 6.4.2 Global Anti-inflammatory and Antipyretic Granules Sales Value by Region (2027-2032)
  9. 6.5 Global Anti-inflammatory and Antipyretic Granules Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Anti-inflammatory and Antipyretic Granules Sales Value (2021-2032)
  12. 6.6.2 North America Anti-inflammatory and Antipyretic Granules Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Anti-inflammatory and Antipyretic Granules Sales Value (2021-2032)
  15. 6.7.2 Europe Anti-inflammatory and Antipyretic Granules Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Anti-inflammatory and Antipyretic Granules Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Anti-inflammatory and Antipyretic Granules Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Anti-inflammatory and Antipyretic Granules Sales Value (2021-2032)
  21. 6.9.2 South America Anti-inflammatory and Antipyretic Granules Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Anti-inflammatory and Antipyretic Granules Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Anti-inflammatory and Antipyretic Granules Sales Value Share by Country, 2025 VS 2032
7 Anti-inflammatory and Antipyretic Granules Country-level Sales and Value Analysis
  1. 7.1 Global Anti-inflammatory and Antipyretic Granules Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Anti-inflammatory and Antipyretic Granules Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Anti-inflammatory and Antipyretic Granules Sales by Country (2021-2032)
  4. 7.3.1 Global Anti-inflammatory and Antipyretic Granules Sales by Country (2021-2026)
  5. 7.3.2 Global Anti-inflammatory and Antipyretic Granules Sales by Country (2027-2032)
  6. 7.4 Global Anti-inflammatory and Antipyretic Granules Sales Value by Country (2021-2032)
  7. 7.4.1 Global Anti-inflammatory and Antipyretic Granules Sales Value by Country (2021-2026)
  8. 7.4.2 Global Anti-inflammatory and Antipyretic Granules Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Anti-inflammatory and Antipyretic Granules Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Anti-inflammatory and Antipyretic Granules Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Anti-inflammatory and Antipyretic Granules Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Dong'e Ejiao Co., Ltd.
  2. 8.1.1 Dong'e Ejiao Co., Ltd. Company Information
  3. 8.1.2 Dong'e Ejiao Co., Ltd. Business Overview
  4. 8.1.3 Dong'e Ejiao Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Dong'e Ejiao Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Portfolio
  6. 8.1.5 Dong'e Ejiao Co., Ltd. Recent Developments
  7. 8.2 Guangdong Baihe Pharmaceutical Co., Ltd.
  8. 8.2.1 Guangdong Baihe Pharmaceutical Co., Ltd. Company Information
  9. 8.2.2 Guangdong Baihe Pharmaceutical Co., Ltd. Business Overview
  10. 8.2.3 Guangdong Baihe Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Guangdong Baihe Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Portfolio
  12. 8.2.5 Guangdong Baihe Pharmaceutical Co., Ltd. Recent Developments
  13. 8.3 Guangxi Tiantianle Pharmaceutical Co., Ltd.
  14. 8.3.1 Guangxi Tiantianle Pharmaceutical Co., Ltd. Company Information
  15. 8.3.2 Guangxi Tiantianle Pharmaceutical Co., Ltd. Business Overview
  16. 8.3.3 Guangxi Tiantianle Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Guangxi Tiantianle Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Portfolio
  18. 8.3.5 Guangxi Tiantianle Pharmaceutical Co., Ltd. Recent Developments
  19. 8.4 Hebei Tiancheng Pharmaceutical Co., Ltd.
  20. 8.4.1 Hebei Tiancheng Pharmaceutical Co., Ltd. Company Information
  21. 8.4.2 Hebei Tiancheng Pharmaceutical Co., Ltd. Business Overview
  22. 8.4.3 Hebei Tiancheng Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Hebei Tiancheng Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Portfolio
  24. 8.4.5 Hebei Tiancheng Pharmaceutical Co., Ltd. Recent Developments
  25. 8.5 Hubei Dongxin Pharmaceutical Co., Ltd.
  26. 8.5.1 Hubei Dongxin Pharmaceutical Co., Ltd. Company Information
  27. 8.5.2 Hubei Dongxin Pharmaceutical Co., Ltd. Business Overview
  28. 8.5.3 Hubei Dongxin Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Hubei Dongxin Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Portfolio
  30. 8.5.5 Hubei Dongxin Pharmaceutical Co., Ltd. Recent Developments
  31. 8.6 Hubei Nordeson Pharmaceutical Co., Ltd.
  32. 8.6.1 Hubei Nordeson Pharmaceutical Co., Ltd. Company Information
  33. 8.6.2 Hubei Nordeson Pharmaceutical Co., Ltd. Business Overview
  34. 8.6.3 Hubei Nordeson Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Hubei Nordeson Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Portfolio
  36. 8.6.5 Hubei Nordeson Pharmaceutical Co., Ltd. Recent Developments
  37. 8.7 Jilin Xianfeng Technology Pharmaceutical Co., Ltd.
  38. 8.7.1 Jilin Xianfeng Technology Pharmaceutical Co., Ltd. Company Information
  39. 8.7.2 Jilin Xianfeng Technology Pharmaceutical Co., Ltd. Business Overview
  40. 8.7.3 Jilin Xianfeng Technology Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Jilin Xianfeng Technology Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Portfolio
  42. 8.7.5 Jilin Xianfeng Technology Pharmaceutical Co., Ltd. Recent Developments
  43. 8.8 Jiangxi Jimin Kexin Pharmaceutical Co., Ltd.
  44. 8.8.1 Jiangxi Jimin Kexin Pharmaceutical Co., Ltd. Company Information
  45. 8.8.2 Jiangxi Jimin Kexin Pharmaceutical Co., Ltd. Business Overview
  46. 8.8.3 Jiangxi Jimin Kexin Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Jiangxi Jimin Kexin Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Portfolio
  48. 8.8.5 Jiangxi Jimin Kexin Pharmaceutical Co., Ltd. Recent Developments
  49. 8.9 Liaoning Xingao Pharmaceutical Co., Ltd.
  50. 8.9.1 Liaoning Xingao Pharmaceutical Co., Ltd. Company Information
  51. 8.9.2 Liaoning Xingao Pharmaceutical Co., Ltd. Business Overview
  52. 8.9.3 Liaoning Xingao Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Liaoning Xingao Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Portfolio
  54. 8.9.5 Liaoning Xingao Pharmaceutical Co., Ltd. Recent Developments
  55. 8.10 Nanning Kangnuo Biochemical Pharmaceutical Co., Ltd.
  56. 8.10.1 Nanning Kangnuo Biochemical Pharmaceutical Co., Ltd. Company Information
  57. 8.10.2 Nanning Kangnuo Biochemical Pharmaceutical Co., Ltd. Business Overview
  58. 8.10.3 Nanning Kangnuo Biochemical Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Nanning Kangnuo Biochemical Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Portfolio
  60. 8.10.5 Nanning Kangnuo Biochemical Pharmaceutical Co., Ltd. Recent Developments
  61. 8.11 Shaanxi Buchang Pharmaceutical Co., Ltd.
  62. 8.11.1 Shaanxi Buchang Pharmaceutical Co., Ltd. Company Information
  63. 8.11.2 Shaanxi Buchang Pharmaceutical Co., Ltd. Business Overview
  64. 8.11.3 Shaanxi Buchang Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Shaanxi Buchang Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Portfolio
  66. 8.11.5 Shaanxi Buchang Pharmaceutical Co., Ltd. Recent Developments
  67. 8.12 Shaanxi Han Tang Pharmaceutical Co., Ltd.
  68. 8.12.1 Shaanxi Han Tang Pharmaceutical Co., Ltd. Company Information
  69. 8.12.2 Shaanxi Han Tang Pharmaceutical Co., Ltd. Business Overview
  70. 8.12.3 Shaanxi Han Tang Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Shaanxi Han Tang Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Portfolio
  72. 8.12.5 Shaanxi Han Tang Pharmaceutical Co., Ltd. Recent Developments
  73. 8.13 Shenyang Junyuan Pharmaceutical Co., Ltd.
  74. 8.13.1 Shenyang Junyuan Pharmaceutical Co., Ltd. Company Information
  75. 8.13.2 Shenyang Junyuan Pharmaceutical Co., Ltd. Business Overview
  76. 8.13.3 Shenyang Junyuan Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Shenyang Junyuan Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Portfolio
  78. 8.13.5 Shenyang Junyuan Pharmaceutical Co., Ltd. Recent Developments
  79. 8.14 Sichuan Kelun Pharmaceutical Co., Ltd.
  80. 8.14.1 Sichuan Kelun Pharmaceutical Co., Ltd. Company Information
  81. 8.14.2 Sichuan Kelun Pharmaceutical Co., Ltd. Business Overview
  82. 8.14.3 Sichuan Kelun Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Sichuan Kelun Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Portfolio
  84. 8.14.5 Sichuan Kelun Pharmaceutical Co., Ltd. Recent Developments
  85. 8.15 Sichuan Luye Pharmaceutical Co., Ltd.
  86. 8.15.1 Sichuan Luye Pharmaceutical Co., Ltd. Company Information
  87. 8.15.2 Sichuan Luye Pharmaceutical Co., Ltd. Business Overview
  88. 8.15.3 Sichuan Luye Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Sichuan Luye Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Portfolio
  90. 8.15.5 Sichuan Luye Pharmaceutical Co., Ltd. Recent Developments
  91. 8.16 Yunnan Baiyao Group Co., Ltd.
  92. 8.16.1 Yunnan Baiyao Group Co., Ltd. Company Information
  93. 8.16.2 Yunnan Baiyao Group Co., Ltd. Business Overview
  94. 8.16.3 Yunnan Baiyao Group Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Yunnan Baiyao Group Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Portfolio
  96. 8.16.5 Yunnan Baiyao Group Co., Ltd. Recent Developments
  97. 8.17 Yunnan Longfa Pharmaceutical Co., Ltd.
  98. 8.17.1 Yunnan Longfa Pharmaceutical Co., Ltd. Company Information
  99. 8.17.2 Yunnan Longfa Pharmaceutical Co., Ltd. Business Overview
  100. 8.17.3 Yunnan Longfa Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Yunnan Longfa Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Portfolio
  102. 8.17.5 Yunnan Longfa Pharmaceutical Co., Ltd. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Anti-inflammatory and Antipyretic Granules Value Chain Analysis
  2. 9.1.1 Anti-inflammatory and Antipyretic Granules Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Anti-inflammatory and Antipyretic Granules Sales Mode & Process
  6. 9.2 Anti-inflammatory and Antipyretic Granules Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Anti-inflammatory and Antipyretic Granules Distributors
  9. 9.2.3 Anti-inflammatory and Antipyretic Granules Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst